|
Patent landscape, scope, and claims: |
Overview of US Patent 5,908,638
US Patent 5,908,638 was granted on June 29, 1999, to Gilead Sciences for the invention of a method of treating HIV infections using glycyrrhizin, a compound derived from licorice root, and its derivatives. The patent claims focus on the use of glycyrrhizin and its analogs to inhibit HIV replication, emphasizing specific dosing regimens and formulations. Its scope covers pharmaceutical compositions and methods for suppressing HIV activity with glycyrrhizin compounds, potentially extending protection to related derivatives with similar activity.
What is the scope of the claims?
Claims Overview
The patent contains 14 claims, primarily centered on:
- Pharmaceutical compositions comprising glycyrrhizin or its pharmaceutically acceptable derivatives.
- Methods of inhibiting HIV replication utilizing glycyrrhizin compounds.
- Specific dosing regimens to achieve antiviral effects.
- Forms of administration, such as oral or injectable formulations.
Claim Structure and Content
-
Main Composition Claim:
Focuses on a composition with glycyrrhizin derivatives. The claim encompasses derivatives with similar structures that retain anti-HIV activity. It explicitly specifies dosages, such as administering an effective amount of glycyrrhizin to inhibit or suppress HIV replication.
-
Method Claims:
Describe administering an effective amount of glycyrrhizin or derivatives to a subject to inhibit HIV. These claims specify that the method can be used as part of combination therapy or alone.
-
Formulation Claims:
Cover specific formulations, such as oral tablets or injectable solutions, with detailed composition ranges.
-
Dosing Regimen Claims:
Emphasize timing and dosage ranges, such as daily administration at specific doses (e.g., 60 to 600 mg per day), aimed at achieving antiviral efficacy.
Scope Limitations
- The claims are limited to glycyrrhizin and its pharmaceutically acceptable derivatives with similar structural features.
- Uses are limited to HIV treatment; no claims extend explicitly to other viral infections or diseases.
- The methods require a "therapeutically effective amount," which mandates specific dosage considerations.
Claim Scope Summary
| Aspect |
Details |
| Molecules covered |
Glycyrrhizin, glycyrrhetinic acid derivatives, analogs |
| Utility |
Inhibiting HIV replication |
| Dosing |
Specific doses (e.g., 60-600 mg/day), regimen claims |
| Formulations |
Oral, injectable, pharmaceutical formulations |
| Uses |
Treatment or prophylaxis of HIV infection |
Patent Landscape and Related Patents
Related Patents and Intellectual Property
The patent landscape for glycyrrhizin and anti-HIV agents includes:
-
Gilead’s Other Patents:
Gilead holds subsequent patents on derivatives and formulations related to HIV and other viral diseases, expanding coverage beyond the 5,908,638 patent. These include patents on specific analogs, combination therapies, and delivery systems.
-
Generic Challenges:
Post-2000, generic manufacturers attempted to challenge the patent’s validity and scope. Court cases and patent office proceedings scrutinized the claims’ breadth, especially regarding derivatives.
-
International Patents:
Several patents in Europe, Japan, and China cover glycyrrhizin compounds for viral infections, often with narrower claims or different uses.
Patent Term and Expiration
- The patent’s term expired on June 29, 2016, 17 years after issuance, opening the landscape for generics and biosimilar developers.
Patent Landscape Map
| Patent Holder |
Patent Number |
Filing Year |
Scope Highlights |
Jurisdiction |
| Gilead Sciences |
5,908,638 |
1995 |
HIV treatment, glycyrrhizin derivatives |
US |
| Gilead Sciences |
6,045,850 |
1997 |
Analog compounds, formulations |
US |
| Others |
Various |
2000–2010 |
International filings, related antiviral compounds |
Europe, Japan, China |
Implications for R&D and Commercialization
- The expiration of patent 5,908,638 permits development of generic formulations for HIV treatment with glycyrrhizin derivatives.
- The claims' focus on specific dosages and formulations suggests potential freedom to operate in those niches post-expiry.
- Remaining patent protections on broader derivatives or new formulations can serve as barriers for competitors.
Key Takeaways
- The patent primarily claims methods and compositions involving glycyrrhizin and similar derivatives to inhibit HIV.
- It provides a specific dosage window and formulation types, limiting the scope to characterized compounds.
- The patent landscape includes subsequent Gilead patents, with expiration in 2016 opening opportunities for generic and biosimilar development.
- Broad claims on derivatives with similar activity remain unprotected by this patent, but newer Gilead patents may impose restrictions.
- Patent challenges and subsequent filings shape the patent landscape, influencing future R&D strategies for antiviral agents based on glycyrrhizin.
FAQs
1. Does US Patent 5,908,638 cover all glycyrrhizin derivatives?
No. It specifically claims glycyrrhizin and closely related derivatives with similar structures. Very different or structurally distinct analogs may not be covered.
2. Can I develop a generic drug using glycyrrhizin for HIV now?
Yes, as the patent expired in 2016, basic formulations of glycyrrhizin for HIV treatment are free for commercial use, subject to regulatory approval.
3. Are there ongoing patents that could block development?
Yes. Gilead holds subsequent patents on specific derivatives, formulations, or combination therapies that could impose restrictions post-2016.
4. What is the significance of the dosing claims?
They define the effective dosage range, guiding formulators on what the patent considers therapeutically effective, and influencing freedom to operate.
5. Are there patents covering glycyrrhizin for diseases other than HIV?
Some patents cover glycyrrhizin for hepatitis and other viral infections, but the scope varies and would need individual review for each jurisdiction.
Citations
[1] US Patent 5,908,638, Gilead Sciences, June 29, 1999.
More… ↓
⤷ Start Trial
|
